ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
P.
Jiménez Fonseca
Publicaciones en las que colabora con P. Jiménez Fonseca (28)
2024
-
Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival
European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 62-74
2023
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
-
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study
The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194
-
MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms
Molecular Oncology, Vol. 17, Núm. 4, pp. 582-597
-
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2692-2706
2022
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
The oncologist, Vol. 27, Núm. 4, pp. e328-e339
-
The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms
European Journal of Cancer, Vol. 168, pp. 80-90
2021
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
-
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Pancreatology, Vol. 21, Núm. 1, pp. 215-223
2020
-
Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas
Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909
-
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Oncologist, Vol. 25, Núm. 9, pp. 745-e1265
2019
-
Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review
Therapeutic Advances in Endocrinology and Metabolism, Vol. 10
-
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544
-
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580
-
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 55-63
2018
-
Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Revisiones en Cancer, Vol. 32, Núm. 5, pp. 277-286
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
-
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours
Cancer Treatment Reviews, Vol. 70, pp. 209-222
2017
-
Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors
Current Oncology Reports, Vol. 19, Núm. 11